A trace of blood in the stool, a mild stomach ache, and a persistent urge to pass motion. Most Malaysians would dismiss these ...

Exact Sciences has a multipronged approach to cancer testing. Its flagship product line is Cologuard, the market leader in stool-based screening for colorectal cancer, or CRC. Its second-largest ...

The second-most common cancer in Malaysia may not have symptoms, which is why experts advocate checkups for early detection.

Simone Ledward Boseman secretly married Chadwick Boseman before his August 2020 death. Here's everything to know about ...

Among 997 patients with lung cancer, only 35.1% met USPSTF screening criteria, while universal age-based screening (40-85 ...

Exact Sciences markets Cologuard as a non-invasive, convenient test. The traditional method of testing for colorectal cancer ...

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and ...

Abbott Laboratories to acquire cancer diagnostics company for $105 per share in deal valued at $21 billion. Closing expected Q2 2026.

Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.

Abbott said on Thursday it would buy cancer test maker Exact Sciences in a deal valued at up to $23 billion, including debt, ...

"Not all colon polyps are cancerous but all colon cancer starts as a polyp which is why everyone needs to know about them and ...

Medical device maker Abbott Laboratories is nearing a potential takeover of cancer test maker Exact Sciences Corp , Bloomberg ...